Skip to main content
. 2022 Mar 25;2022:4233782. doi: 10.1155/2022/4233782

Table 4.

Tumor response in patients receiving ≤3 lines and >3 lines treatment.

Best response ≤3 lines >3 lines
CR, n 0 0
PR, n 5 1
SD, n 5 6
PD, n 4 4
ORR, n (%) 35.7% 9.1%
DCR, n (%) 71.4% 63.6%